Drug General Information
Drug ID	D0L6LD
Former ID	DIB012379
Drug Name	AZD-3199
Indication	Asthma [ICD10:J45]		Phase 2	[522407]
Structure		Download 2D MOL
Target and Pathway
Target(s)	Beta-2 adrenergic receptor	Target Info	Agonist	[544464]
KEGG Pathway	Calcium signaling pathway
	cGMP-PKG signaling pathway
	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	Endocytosis
	Adrenergic signaling in cardiomyocytes
	Salivary secretion
NetPath Pathway	TCR Signaling Pathway
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
	Beta2 adrenergic receptor signaling pathway
Pathway Interaction Database	Arf6 trafficking events
	Arf6 signaling events
Reactome	Adrenoceptors
	G alpha (s) signalling events
WikiPathways	Monoamine GPCRs
	Calcium Regulation in the Cardiac Cell
	GPCRs, Class A Rhodopsin-like
	Vitamin D Receptor Pathway
	GPCR ligand binding
	GPCR downstream signaling
	GPCRs, Other
References
Ref 522407	ClinicalTrials.gov (NCT00736489) Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199. U.S. National Institutes of Health.
Ref 544464	Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting beta2-adrenoreceptor agonist (uLABA). Drug Des Devel Ther. 2015; 9: 753-762.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.